Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals Key Statistics
Pro Data ExportCurrent Valuation
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | -9956% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 12.37 |
| Debt to Equity Ratio | 0.0912 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -0.62% |
| Year to Date Stock Returns | 24.81% |
| 1 Year Stock Returns | 11.81% |
| 3 Year Stock Returns | 15.83% |
| 52 Week High | 1.95 |
| 52 Week Low | 0.8103 |
Income Statement
| Revenues TTM | 1.553M |
| Revenue Per Share TTM | 0.0032 |
| Revenue Growth | -49.66% |
| Gross Profit TTM | 1.553M |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | -116.45M |
| Earnings Per Share TTM | -0.31 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | -54.30M |
| Cash Financing TTM | 156.59M |
| Cash Operations TTM | -93.40M |
| Capital Expenditures | 0.234M |
Share Statistics
| Shares Outstanding | 480.56M |
Balance Sheet
| Cash and ST Investments | 253.66M |
| Total Assets | 402.79M |
| Liabilities | 133.82M |
| Book Value | 268.97M |
| Book Value per Share | 0.5597 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 24.54M |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these LXRX related companies
LXRX News
$LXRX forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3rh7
about 13 days ago by RecogniaEvents
about 13 days ago by RecogniaEvents
Lexicon Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
May 03, 7:00PM Seeking Alpha
May 03, 7:00PM Seeking Alpha
Listen to $LXRX Q1 2012 earnings call - live at 11:00 AM, ondemand after - http://stks.co/3ePP
about 27 days ago by earningscast
about 27 days ago by earningscast
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
May 03, 7:03AM Benzinga
May 03, 7:03AM Benzinga
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
May 03, 6:00AM PR Newswire
May 03, 6:00AM PR Newswire
Lexicon Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Mar 27, 6:00PM PR Newswire
Mar 27, 6:00PM PR Newswire
FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
Mar 20, 6:00PM PR Newswire
Mar 20, 6:00PM PR Newswire
$LXRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/2tlK
about 75 days ago by MarketBrief
about 75 days ago by MarketBrief
Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 29, 6:00PM PR Newswire
Feb 29, 6:00PM PR Newswire
Lexicon Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 22, 5:10PM Seeking Alpha
Feb 22, 5:10PM Seeking Alpha
Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
Feb 16, 6:31PM PR Newswire
Feb 16, 6:31PM PR Newswire
@greglaw $lxrx moving averages really don't work on biotech companies. It is all about funding!
about 105 days ago by hedgeflight
about 105 days ago by hedgeflight
@ChimeraResearch $lxrx How can you say it is overvalued? They have 2 drugs that will be in phase 3 later this year. Plus they have cash.
about 105 days ago by hedgeflight
about 105 days ago by hedgeflight
$lxrx add to position as phase 3 trials to begin in late 2012 and diabetes drug has huge potential.
about 105 days ago by hedgeflight
about 105 days ago by hedgeflight
Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 07, 6:00PM PR Newswire
Feb 07, 6:00PM PR Newswire
Lexicon Pharmaceuticals' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Jan 11, 8:42PM Seeking Alpha
Jan 11, 8:42PM Seeking Alpha
$LXRX http://stks.co/1snv long setup picking up steam.... on the radar
about 140 days ago by stt2318
about 140 days ago by stt2318
Lexicon (LXRX) Says Top-Line Results from LX4211 Study Show Enhanced Effects with DPP-4
Jan 09, 4:41PM Street Insider
Jan 09, 4:41PM Street Insider
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Jan 09, 4:30PM Benzinga
Jan 09, 4:30PM Benzinga
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 04, 6:00PM PR Newswire
Jan 04, 6:00PM PR Newswire
Lexicon Pharmaceuticals (LXRX) Completes Offering with Gross Proceeds of $161 Million
Dec 23, 8:31AM Street Insider
Dec 23, 8:31AM Street Insider
FMR LLC Raises Stake in Lexicon Pharmaceuticals, Inc. (LXRX) to 17.55%
Dec 12, 11:43AM Street Insider
Dec 12, 11:43AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LXRX | 1.61 | +0.01 | +0.62% | 773.70M |
| LXP | 8.30 | -0.09 | -1.07% | 1.290B |
| LSTR | 54.12 | +0.51 | +0.95% | 2.528B |
| LSI | 6.85 | -0.05 | -0.72% | 3.882B |
| LSG | 0.8744 | -0.02 | -1.75% | 358.71M |
| LSCC | 4.55 | +0.03 | +0.66% | 538.81M |
| LSBK | 9.23 | -0.77 | -7.70% | 54.83M |
| LOOP | 19.17 | +0.00 | +0.00% | 675.55M |
| LOOK | 0.80 | +0.02 | +2.58% | 13.83M |
| LONG | 13.96 | -0.02 | -0.14% | 471.85M |
